Suppr超能文献

相似文献

2
Ceramide-Rubusoside Nanomicelles, a Potential Therapeutic Approach to Target Cancers Carrying p53 Missense Mutations.
Mol Cancer Ther. 2020 Feb;19(2):564-574. doi: 10.1158/1535-7163.MCT-19-0366. Epub 2019 Oct 23.
3
Mutant p53 gain-of-function in cancer.
Cold Spring Harb Perspect Biol. 2010 Feb;2(2):a001107. doi: 10.1101/cshperspect.a001107.
4
Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors.
Mol Cancer Res. 2014 Jun;12(6):901-11. doi: 10.1158/1541-7786.MCR-14-0089. Epub 2014 Mar 5.
7
Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery.
Nanomedicine. 2024 Feb;56:102732. doi: 10.1016/j.nano.2024.102732. Epub 2024 Jan 8.
8
Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice.
PLoS One. 2015 Feb 19;10(2):e0118029. doi: 10.1371/journal.pone.0118029. eCollection 2015.
9
Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.
Cold Spring Harb Perspect Med. 2017 Feb 1;7(2):a026054. doi: 10.1101/cshperspect.a026054.

引用本文的文献

1
Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation.
Biomark Res. 2025 Aug 27;13(1):111. doi: 10.1186/s40364-025-00826-7.
4
p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis.
Cancer Res Commun. 2023 Dec 29;3(12):2640-2652. doi: 10.1158/2767-9764.CRC-23-0218.
5
Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis.
Cell Death Dis. 2023 Jul 27;14(7):476. doi: 10.1038/s41419-023-05958-y.
7
New potential targeted strategies in small cell lung cancer.
Transl Lung Cancer Res. 2023 Apr 28;12(4):661-664. doi: 10.21037/tlcr-23-64. Epub 2023 Apr 4.
8
TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Biomedicines. 2023 Apr 11;11(4):1152. doi: 10.3390/biomedicines11041152.
10
Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53.
Cancers (Basel). 2022 Oct 22;14(21):5176. doi: 10.3390/cancers14215176.

本文引用的文献

1
Mdm2 and Mdm4 loss regulates distinct p53 activities.
Mol Cancer Res. 2008 Jun;6(6):947-54. doi: 10.1158/1541-7786.MCR-07-2079.
2
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.
Genes Dev. 2008 May 15;22(10):1337-44. doi: 10.1101/gad.1662908.
3
P53 promoter selection: choosing between life and death.
Cell Cycle. 2008 Jan 15;7(2):154-7. doi: 10.4161/cc.7.2.5236. Epub 2007 Oct 22.
4
Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development.
Mol Cell Biol. 2007 Aug;27(15):5479-85. doi: 10.1128/MCB.00555-06. Epub 2007 May 25.
6
p53 induced growth arrest versus apoptosis and its modulation by survival cytokines.
Cell Cycle. 2007 Jan 15;6(2):166-70. doi: 10.4161/cc.6.2.3789. Epub 2007 Jan 29.
7
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.
Nature. 2007 Feb 8;445(7128):656-60. doi: 10.1038/nature05529. Epub 2007 Jan 24.
8
Restoration of p53 function leads to tumour regression in vivo.
Nature. 2007 Feb 8;445(7128):661-5. doi: 10.1038/nature05541. Epub 2007 Jan 24.
9
The oncogenic roles of p53 mutants in mouse models.
Curr Opin Genet Dev. 2007 Feb;17(1):66-70. doi: 10.1016/j.gde.2006.12.003. Epub 2007 Jan 8.
10
Modeling the therapeutic efficacy of p53 restoration in tumors.
Cell. 2006 Dec 29;127(7):1323-34. doi: 10.1016/j.cell.2006.12.007. Epub 2006 Dec 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验